Faubert, B., Solmonson, A. & DeBerardinis, R. J. Metabolic reprogramming and cancer progression. Science. 368, (2020).
Sun, L., Zhang, H. & Gao, P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 13, 877–919 (2022).
Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018).
Ren, J. et al. Crosstalk between metabolic remodeling and epigenetic reprogramming: A new perspective on pancreatic cancer. Cancer Lett. 587, 216649 (2024).
Yuan, H. et al. Lysine catabolism reprograms tumour immunity through histone crotonylation. Nature 617, 818–826 (2023).
Sun, Y. et al. Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma. Cancer Cell. 42, 135–156.e117 (2024).
Halbrook, C. J. et al. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Nat. Cancer 3, 1386–1403 (2022).
Lin, K. X. et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunol. Immunother. 72, 3875–3893 (2023).
Liu, S. J. et al. Safety, efficacy, and survival outcomes of immune checkpoint inhibitors rechallenge in patients with cancer: a systematic review and meta-analysis. Oncologist 29, e1425–e1434 (2024).
Warburg, O. On the Origin of Cancer Cells. Science 123, 309–314 (1956).
Mark, H. R., Lasser, E. C. & Pittman, L. C. The role of glycolysis in the survival of cancer cells. Cancer Res. 36, 4397–4403 (1976).
Porporato, P. aoloE. et al. A Mitochondrial Switch Promotes Tumor Metastasis. Cell Rep. 8, 754–766 (2014).
Chen, E. I. et al. Adaptation of energy metabolism in breast cancer brain metastases. Cancer Res. 67, 1472–1486 (2007).
Dornier, E. et al. Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat. Commun. 8, 2255 (2017).
Antalis, C. J., Uchida, A., Buhman, K. K. & Siddiqui, R. A. Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. Clin. Exp. Metastasis. 28, 733–741 (2011).
Elia, I. et al. Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat. Commun. 8, 15267 (2017).
Zhang, L. et al. Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33, 1111–1123.e1114 (2021).
Christen, S. et al. Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Rep. 17, 837–848 (2016).
Knudson, A. G. Mutation and Cancer: Statistical Study of Retinoblastoma. Proc. Natl Acad. Sci. 68, 820–823 (1971).
Bird, A. P. DNA methylation and the frequency of CpG in animal DNA. Nucleic Acids Res. 8, 1499–1504 (1980).
Flavahan, W. A., Gaskell, E. & Bernstein, B. E. Epigenetic plasticity and the hallmarks of cancer. Science. 357, (2017).
Conte, M. & Altucci, L. Molecular Pathways: The Complexity of the Epigenome in Cancer and Recent Clinical Advances. Clin. Cancer Res. 18, 5526–5534 (2012).
Janzen, W. P., Wigle, T. J., Jin, J. & Frye, S. V. Epigenetics: Tools and Technologies. Drug Discov. Today Technol. 7, e59–e65 (2010).
Liu, X. et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 451, 846–850 (2008).
Cheung, N. et al. Protein arginine-methyltransferase-dependent oncogenesis. Nat. Cell Biol. 9, 1208–1215 (2007).
Su, I. H. et al. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4, 124–131 (2003).
Hsia, D. A. et al. KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation. Proc. Natl Acad. Sci. USA. 107, 9671–9676 (2010).
Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 13, 1–27 (1970).
Doherty, P. C. & Zinkernagel, R. M. Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature 256, 50–52 (1975).
Freeman, G. J. et al. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation. J. Exp. Med. 192, 1027–1034 (2000).
Schreiber, R. D., Old, L. J. & Smyth, M. J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).
Zhang, Z. et al. Identification of lysine succinylation as a new post-translational modification. Nat. Chem. Biol. 7, 58–63 (2011).
Hirschey, M. D. & Zhao, Y. Metabolic Regulation by Lysine Malonylation, Succinylation, and Glutarylation. Mol. Cell Proteom. 14, 2308–2315 (2015).
Zhang, D. et al. Metabolic regulation of gene expression by histone lactylation. Nature 574, 575–580 (2019).
Yang, Y. et al. Lactate and lysine lactylation of histone regulate transcription in cancer. Heliyon 10, e38426 (2024).
Chen, A. N. et al. Lactylation, a Novel Metabolic Reprogramming Code: Current Status And Prospects. Front Immunol. 12, 688910 (2021).
Zhang, C. et al. H3K18 Lactylation Potentiates Immune Escape of Non-Small Cell Lung Cancer. Cancer Res. 84, 3589–3601 (2024).
De Leo, A. et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity 57, 1105–1123.e1108 (2024).
Zhu, R. et al. ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. 37, 361–376.e367 (2025).
Zhao, Q. et al. Nonenzymatic lysine d-lactylation induced by glyoxalase II substrate SLG dampens inflammatory immune responses. Cell Res. 35, 97–116 (2025).
Linder, M. E. & Deschenes, R. J. Palmitoylation: policing protein stability and traffic. Nat. Rev. Mol. Cell Biol. 8, 74–84 (2007).
Babina, I. S. et al. A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Res. 16, R19 (2014).
Chen, Y. et al. Lysine Propionylation and Butyrylation Are Novel Post-translational Modifications in Histones*. Mol. Cell Proteom. 6, 812–819 (2007).
Gates, L. A. et al. Histone butyrylation in the mouse intestine is mediated by the microbiota and associated with regulation of gene expression. Nat. Metab. 6, 697–707 (2024).
Xie, Z. et al. Lysine succinylation and lysine malonylation in histones. Mol. Cell Proteom. 11, 100–107 (2012).
Colak, G. et al. Proteomic and Biochemical Studies of Lysine Malonylation Suggest Its Malonic Aciduria-associated Regulatory Role in Mitochondrial Function and Fatty Acid Oxidation. Mol. Cell Proteom. 14, 3056–3071 (2015).
Dai, L. et al. Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark. Nat. Chem. Biol. 10, 365–370 (2014).
Huang, H. et al. p300-Mediated Lysine 2-Hydroxyisobutyrylation Regulates Glycolysis. Mol. Cell. 70, 663–678.e666 (2018).
Xie, Z. et al. Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation. Mol. Cell. 62, 194–206 (2016).
Qin, J. et al. Ketogenic diet reshapes cancer metabolism through lysine β-hydroxybutyrylation. Nat. Metab. 6, 1505–1528 (2024).
Tan, M. et al. Lysine glutarylation is a protein posttranslational modification regulated by SIRT5. Cell Metab. 19, 605–617 (2014).
Bao, X. et al. Glutarylation of Histone H4 Lysine 91 Regulates Chromatin Dynamics. Mol. Cell. 76, 660–675.e669 (2019).
Xie, J. -y. et al. The mechanisms, regulations, and functions of histone lysine crotonylation. Cell Death Dis. 10, 66 (2024).
Gantner, B. N. et al. Histone oxidation as a new mechanism of metabolic control over gene expression. Trends Genet. 40, 739–746 (2024).
Nůsková, H. et al. Stearic acid blunts growth-factor signaling via oleoylation of GNAI proteins. Nat. Commun. 12, 4590 (2021).
Drummond, D. C. et al. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev. Pharm. Toxicol. 45, 495–528 (2005).
McDermott, D. F. & Atkins, M. B. PD-1 as a potential target in cancer therapy. Cancer Med. 2, 662–673 (2013).
Henning, A. N., Roychoudhuri, R. & Restifo, N. P. Epigenetic control of CD8+ T cell differentiation. Nat. Rev. Immunol. 18, 340–356 (2018).
Goell, J. H. & Hilton, I. B. CRISPR/Cas-Based Epigenome Editing: Advances, Applications, and Clinical Utility. Trends Biotechnol. 39, 678–691 (2021).
Li, N. et al. ARID1A loss induces polymorphonuclear myeloid-derived suppressor cell chemotaxis and promotes prostate cancer progression. Nat. Commun. 13, 7281 (2022).
Yu, X. et al. Cancer epigenetics: from laboratory studies and clinical trials to precision medicine. Cell Death Dis. 10, 28 (2024).
Chang, C. H. et al. Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell 162, 1229–1241 (2015).
Bunse, L. et al. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate. Nat. Med. 24, 1192–1203 (2018).
Ganeshan, K. & Chawla, A. Metabolic regulation of immune responses. Annu Rev. Immunol. 32, 609–634 (2014).
Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781–790 (2014).
Bordon, Y. Air miles for T cells. Nat. Rev. Immunol. 13, 705–705 (2013).
Keerthana, C. K. et al. The role of AMPK in cancer metabolism and its impact on the immunomodulation of the tumor microenvironment. Front Immunol. 14, 1114582 (2023).
Cerezo, M. & Rocchi, S. Cancer cell metabolic reprogramming: a keystone for the response to immunotherapy. Cell Death Dis. 11, 964 (2020).
Xia, L. et al. The cancer metabolic reprogramming and immune response. Mol. Cancer 20, 28 (2021).
Dong, C. et al. Loss of FBP1 by Snail-mediated repression provides metabolic advantages in basal-like breast cancer. Cancer Cell. 23, 316–331 (2013).
Mihaylova, M. M. & Shaw, R. J. Metabolic reprogramming by class I and II histone deacetylases. Trends Endocrinol. Metab. 24, 48–57 (2013).
Bracken, C. P., Scott, H. S. & Goodall, G. J. A network-biology perspective of microRNA function and dysfunction in cancer. Nat. Rev. Genet. 17, 719–732 (2016).
DiNardo, C. D. et al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. Lancet Oncol. 22, 1597–1608 (2021).
Bannister, A. J. & Kouzarides, T. Regulation of chromatin by histone modifications. Cell Res. 21, 381–395 (2011).
Ravanel, S., Gakière, B., Job, D. & Douce, R. The specific features of methionine biosynthesis and metabolism in plants. Proc. Natl Acad. Sci. USA. 95, 7805–7812 (1998).
Sanderson, S. M., Gao, X., Dai, Z. & Locasale, J. W. Methionine metabolism in health and cancer: a nexus of diet and precision medicine. Nat. Rev. Cancer 19, 625–637 (2019).
Shyh-Chang, N. et al. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science 339, 222–226 (2013).
Haws, S. A. et al. Methyl-Metabolite Depletion Elicits Adaptive Responses to Support Heterochromatin Stability and Epigenetic Persistence. Mol. Cell. 78, 210–223.e218 (2020).
Sperber, H. et al. The metabolome regulates the epigenetic landscape during naive-to-primed human embryonic stem cell transition. Nat. Cell Biol. 17, 1523–1535 (2015).
Larson, A. G. et al. Liquid droplet formation by HP1α suggests a role for phase separation in heterochromatin. Nature 547, 236–240 (2017).
You, M. et al. Signaling pathways in cancer metabolism: mechanisms and therapeutic targets. Signal Transduct. Target Ther. 8, 196 (2023).
Gräff, J. & Tsai, L.-H. Histone acetylation: molecular mnemonics on the chromatin. Nat. Rev. Neurosci. 14, 97–111 (2013).
Imai, S. -i & Guarente, L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24, 464–471 (2014).
Wang, Y. P. & Lei, Q. Y. Metabolite sensing and signaling in cell metabolism. Signal Transduct. Target Ther. 3, 30 (2018).
Xiong, Q. et al. Metabolite-Sensing G Protein Coupled Receptor TGR5 Protects Host From Viral Infection Through Amplifying Type I Interferon Responses. Front Immunol. 9, 2289 (2018).
Honn, K. V. et al. 12-HETER1/GPR31, a high-affinity 12(S)-hydroxyeicosatetraenoic acid receptor, is significantly up-regulated in prostate cancer and plays a critical role in prostate cancer progression. FASEB J. 30, 2360–2369 (2016).
Morita, N. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1(+) cells by bacterial metabolites. Nature 566, 110–114 (2019).
Gilissen, J. et al. Insight into SUCNR1 (GPR91) structure and function. Pharm. Ther. 159, 56–65 (2016).
Klysz, D. et al. Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. Sci. Signal. 8, ra97 (2015).
Johnson, M. O. et al. Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell 175, 1780–1795.e1719 (2018).
Le Poul, E. et al. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278, 25481–25489 (2003).
Lavoie, S. et al. Expression of Free Fatty Acid Receptor 2 by Dendritic Cells Prevents Their Expression of Interleukin 27 and Is Required for Maintenance of Mucosal Barrier and Immune Response Against Colorectal Tumors in Mice. Gastroenterology 158, 1359–1372.e1359 (2020).
Wang, J. et al. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J. Biol. Chem. 281, 34457–34464 (2006).
Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549–554 (2021).
Meunier, G. et al. Antileukemic activity of the VPS34-IN1 inhibitor in acute myeloid leukemia. Oncogenesis 9, 94 (2020).
Cervenka, I., Agudelo, L. Z. & Ruas, J. L. Kynurenines: Tryptophan’s metabolites in exercise, inflammation, and mental health. Science. 357, (2017).
An, Y. J. et al. Lactate as a major epigenetic carbon source for histone acetylation via nuclear LDH metabolism. Exp. Mol. Med. 55, 2238–2247 (2023).
Yin, C. et al. ALDOB/KAT2A interactions epigenetically modulate TGF-β expression and T cell functions in hepatocellular carcinogenesis. Hepatology 81, 77–93 (2025).
Wang, Y. et al. KAT2A coupled with the α-KGDH complex acts as a histone H3 succinyltransferase. Nature 552, 273–277 (2017).
Wang, S. et al. Lactate reprograms glioblastoma immunity through CBX3-regulated histone lactylation. J Clin Invest. 134, (2024).
Li, X. et al. Regulation of chromatin and gene expression by metabolic enzymes and metabolites. Nat. Rev. Mol. Cell Biol. 19, 563–578 (2018).
Chang, H. C. & Guarente, L. SIRT1 and other sirtuins in metabolism. Trends Endocrinol. Metab. 25, 138–145 (2014).
Jing, H. & Lin, H. Sirtuins in Epigenetic Regulation. Chem. Rev. 115, 2350–2375 (2015).
Saravia, J. et al. Signaling networks in immunometabolism. Cell Res. 30, 328–342 (2020).
Bilanges, B., Posor, Y. & Vanhaesebroeck, B. PI3K isoforms in cell signalling and vesicle trafficking. Nat. Rev. Mol. Cell Biol. 20, 515–534 (2019).
Macintyre, A. N. et al. Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. Immunity 34, 224–236 (2011).
Delgoffe, G. M. et al. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 12, 295–303 (2011).
Yang, K. et al. T cell exit from quiescence and differentiation into Th2 cells depend on Raptor-mTORC1-mediated metabolic reprogramming. Immunity 39, 1043–1056 (2013).
Ohteki, T. et al. Negative regulation of T cell proliferation and interleukin 2 production by the serine threonine kinase GSK-3. J. Exp. Med. 192, 99–104 (2000).
Tarasenko, T. N. et al. Cytochrome c Oxidase Activity Is a Metabolic Checkpoint that Regulates Cell Fate Decisions During T Cell Activation and Differentiation. Cell Metab. 25, 1254–1268.e1257 (2017).
Chisolm, D. A. et al. CCCTC-Binding Factor Translates Interleukin 2- and α-Ketoglutarate-Sensitive Metabolic Changes in T Cells into Context-Dependent Gene Programs. Immunity 47, 251–267.e257 (2017).
Ma, E. H. et al. Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 345–357 (2017).
Mak, T. W. et al. Glutathione Primes T Cell Metabolism for Inflammation. Immunity 46, 1089–1090 (2017).
Lin, R. et al. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nat. Cell Biol. 17, 1484–1496 (2015).
Blagih, J. et al. The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo. Immunity 42, 41–54 (2015).
Toyama, E. Q. et al. Metabolism. AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science 351, 275–281 (2016).
Scharping, N. E. et al. The Tumor Microenvironment Represses T Cell Mitochondrial Biogenesis to Drive Intratumoral T Cell Metabolic Insufficiency and Dysfunction. Immunity 45, 701–703 (2016).
Boulikas, T. Nuclear localization signals (NLS). Crit. Rev. Eukaryot. Gene Expr. 3, 193–227 (1993).
Liu, R. et al. Nuclear GTPSCS functions as a lactyl-CoA synthetase to promote histone lactylation and gliomagenesis. Cell Metab. 37, 377–394.e379 (2025).
Yang, Y. et al. Nuclear transport proteins: structure, function and disease relevance. Signal Transduct. Target Ther. 8, 425 (2023).
Liu, H. et al. SNARE proteins: Core engines of membrane fusion in cancer. Biochim Biophys Acta Rev Cancer. 189148, (2024).
Ogrunc, M. et al. Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ. 21, 998–1012 (2014).
Hamarsheh, S. A. et al. Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. Nat. Commun. 11, 1659 (2020).
Singh, A. et al. NRF2 Activation Promotes Aggressive Lung Cancer and Associates with Poor Clinical Outcomes. Clin. Cancer Res. 27, 877–888 (2021).
Keshet, R., Szlosarek, P., Carracedo, A. & Erez, A. Rewiring urea cycle metabolism in cancer to support anabolism. Nat. Rev. Cancer 18, 634–645 (2018).
Lee, J. S. et al. Urea Cycle Dysregulation Generates Clinically Relevant Genomic and Biochemical Signatures. Cell 174, 1559–1570.e1522 (2018).
Chowell, D. et al. TCR contact residue hydrophobicity is a hallmark of immunogenic CD8+ T cell epitopes. Proc. Natl Acad. Sci. USA. 112, E1754–E1762 (2015).
Fendt, S.-M. 100 years of the Warburg effect: A cancer metabolism endeavor. Cell 187, 3824–3828 (2024).
Garcia, S. N., Guedes, R. C. & Marques, M. M. Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics. Curr. Med Chem. 26, 7285–7322 (2019).
Guo, D. et al. Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα. Cell Metab. 34, 1312–1324.e1316 (2022).
Yu, J. et al. Histone lactylation drives oncogenesis by facilitating m(6)A reader protein YTHDF2 expression in ocular melanoma. Genome Biol. 22, 85 (2021).
Wang, X. et al. Histone lactylation dynamics: Unlocking the triad of metabolism, epigenetics, and immune regulation in metastatic cascade of pancreatic cancer. Cancer Lett. 598, 217117 (2024).
Huang, Z. W. et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal Transduct. Target Ther. 8, 391 (2023).
Li, Z. et al. CAF-secreted LOX promotes PD-L1 expression via histone Lactylation and regulates tumor EMT through TGFβ/IGF1 signaling in gastric Cancer. Cell Signal. 124, 111462 (2024).
Yu, Y., Huang, X., Liang, C. & Zhang, P. Evodiamine impairs HIF1A histone lactylation to inhibit Sema3A-mediated angiogenesis and PD-L1 by inducing ferroptosis in prostate cancer. Eur. J. Pharmacol. 957, 176007 (2023).
Chang, C. H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013).
Jiang, F. et al. Characterization of Fatty Acid Metabolism-Related Genes Landscape for Predicting Prognosis and Aiding Immunotherapy in Glioma Patients. Front Immunol. 13, 902143 (2022).
Ferrere, G. et al. Ketogenic diet and ketone bodies enhance the anticancer effects of PD-1 blockade. JCI Insight. 6, (2021).
Ma, X. et al. Cholesterol Induces CD8(+) T Cell Exhaustion in the Tumor Microenvironment. Cell Metab. 30, 143–156.e145 (2019).
Liu, Y. et al. Tumor-Repopulating Cells Induce PD-1 Expression in CD8(+) T Cells by Transferring Kynurenine and AhR Activation. Cancer Cell. 33, 480–494.e487 (2018).
Lv, H. et al. NAD(+) Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion. Cell Metab. 33, 110–127.e115 (2021).
Matés, J. M. et al. Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer. Semin Cell Dev. Biol. 98, 34–43 (2020).
Zhang, X.-Y. et al. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. Cancer Commun. 44, 670–694 (2024).
Röhrig, F. & Schulze, A. The multifaceted roles of fatty acid synthesis in cancer. Nat. Rev. Cancer 16, 732–749 (2016).
Jiang, N. et al. Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion. Nat. Commun. 13, 1511 (2022).
Shang, M. et al. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. Nat. Commun. 12, 1940 (2021).
Li, T. et al. Methionine deficiency facilitates antitumour immunity by altering m(6)A methylation of immune checkpoint transcripts. Gut 72, 501–511 (2023).
Wang, Z. et al. Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity. Embo j, (2024).
Lin, H. et al. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell, (2024).
Jiang, L. et al. Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells. Front Immunol. 9, (2018).
Galluzzi, L. et al. Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17, 97–111 (2017).
Moesta, A. K., Li, X.-Y. & Smyth, M. J. Targeting CD39 in cancer. Nat. Rev. Immunol. 20, 739–755 (2020).
Wu, M.-J. et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science 385, eadl6173 (2024).
Chen, X. et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell 186, 3903–3920.e3921 (2023).
Gu, S. S. et al. Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade. Cancer Discov. 11, 1524–1541 (2021).
Mangalhara, K. C. et al. Manipulating mitochondrial electron flow enhances tumor immunogenicity. Science 381, 1316–1323 (2023).
Zheng, P. et al. Succinate nanomaterials boost tumor immunotherapy via activating cell pyroptosis and Enhancing MHC-I Expression. J. Am. Chem. Soc. 147, 1508–1517 (2025).
Enkler, L. et al. Arf1 coordinates fatty acid metabolism and mitochondrial homeostasis. Nat. Cell Bio. 25, 1157–1172 (2023).
Wang, G. et al. Arf1-mediated lipid metabolism sustains cancer cells and its ablation induces anti-tumor immune responses in mice. Nat. Commun. 11, 220 (2020).
Zhang, S. M. et al. KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. Nature 598, 682–687 (2021).
Sheng, W. et al. LSD1 ablation stimulates anti-tumor immunity and enables checkpoint blockade. Cell 174, 549–563.e519 (2018).
Griffin, G. K. et al. Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity. Nature 595, 309–314 (2021).
Fang, L. et al. Methionine restriction promotes cGAS activation and chromatin untethering through demethylation to enhance antitumor immunity. Cancer Cell. 41, 1118–1133.e1112 (2023).
Saha, S. et al. Serine depletion promotes antitumor immunity by activating mitochondrial DNA-Mediated cGAS-STING Signaling. Cancer Res. 84, 2645–2659 (2024).
Wu, Q. et al. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat. Chem. Biol. 18, 821–830 (2022).
Kohli, K., Pillarisetty, V. G. & Kim, T. S. Key chemokines direct migration of immune cells in solid tumors. Cancer Gene Ther. 29, 10–21 (2022).
Liu, J. et al. QDPR deficiency drives immune suppression in pancreatic cancer. Cell Metab. 36, 984–999.e988 (2024).
Lee, R. et al. Synthetic Essentiality of Tryptophan 2,3-Dioxygenase 2 in APC-Mutated Colorectal Cancer. Cancer Discov. 12, 1702–1717 (2022).
Tang, T. et al. Transcriptional control of pancreatic cancer immunosuppression by metabolic enzyme CD73 in a tumor-autonomous and -autocrine manner. Nat. Commun. 14, 3364 (2023).
Cao, T. et al. Cancer SLC6A6-mediated taurine uptake transactivates immune checkpoint genes and induces exhaustion in CD8+ T cells. Cell 187, 2288–2304.e2227 (2024).
Xu, K. et al. Glycolysis fuels phosphoinositide 3-kinase signaling to bolster T cell immunity. Science 371, 405–410 (2021).
Zhao, D. et al. H3K4me3 Demethylase Kdm5a Is Required for NK Cell Activation by Associating with p50 to Suppress SOCS1. Cell Rep. 15, 288–299 (2016).
Kao, K. C., Vilbois, S., Tsai, C. H. & Ho, P. C. Metabolic communication in the tumour-immune microenvironment. Nat. Cell Biol. 24, 1574–1583 (2022).
Koukourakis, M. I. & Giatromanolaki, A. Tumor draining lymph nodes, immune response, and radiotherapy: Towards a revisal of therapeutic principles. Biochim Biophys. Acta Rev. Cancer 1877, 188704 (2022).
Giatromanolaki, A. et al. Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration. Br. J. Cancer 122, 1205–1210 (2020).
Macintyre, A. ndrewN. et al. The Glucose Transporter Glut1 Is Selectively Essential for CD4 T Cell Activation and Effector Function. Cell Metab. 20, 61–72 (2014).
Brand, A. et al. LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. Cell Metab. 24, 657–671 (2016).
Palazon, A. et al. An HIF-1α/VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. Cancer Cell. 32, 669–683.e665 (2017).
Peralta, R. M. et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nature Immunol, (2024).
Gupta, V. K. et al. Hypoxia-Driven Oncometabolite L-2HG Maintains Stemness-Differentiation Balance and Facilitates Immune Evasion in Pancreatic Cancer. Cancer Res. 81, 4001–4013 (2021).
Konkel, J. E. et al. Transforming Growth Factor-β Signaling in Regulatory T Cells Controls T Helper-17 Cells and Tissue-Specific Immune Responses. Immunity 46, 660–674 (2017).
Ding, R. et al. Lactate modulates RNA splicing to promote CTLA-4 expression in tumor-infiltrating regulatory T cells. Immunity 57, 528–540.e526 (2024).
Kumagai, S. et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 40, 201–218.e209 (2022).
Raychaudhuri, D. et al. Histone lactylation drives CD8(+) T cell metabolism and function. Nat. Immunol. 25, 2140–2151 (2024).
Deng, J. et al. Hypoxia-Induced VISTA Promotes the Suppressive Function of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Cancer Immunol. Res. 7, 1079–1090 (2019).
Liu, N. et al. Lactate inhibits ATP6V0d2 expression in tumor-associated macrophages to promote HIF-2α-mediated tumor progression. J. Clin. Invest. 129, 631–646 (2019).
Gu, J. et al. Tumor-resident microbiota contributes to colorectal cancer liver metastasis by lactylation and immune modulation. Oncogene 43, 2389–2404 (2024).
Xiong, J. et al. Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol. Cell. 82, 1660–1677.e1610 (2022).
Harjunpää, H. et al. Loss of β2-integrin function results in metabolic reprogramming of dendritic cells, leading to increased dendritic cell functionality and anti-tumor responses. Oncoimmunology 13, 2369373 (2024).
Somarribas Patterson, L. F. & Vardhana, S. A. Metabolic regulation of the cancer-immunity cycle. Trends Immunol. 42, 975–993 (2021).
Ryan, D. G. et al. Coupling Krebs cycle metabolites to signalling in immunity and cancer. Nat. Metab. 1, 16–33 (2019).
Wu, J. Y. et al. Cancer-Derived Succinate Promotes Macrophage Polarization and Cancer Metastasis via Succinate Receptor. Mol. Cell. 77, 213–227.e215 (2020).
Jiang, S. S. et al. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Cell Host Microbe 31, 781–797.e789 (2023).
Cheng, J. et al. Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8+ T cells in the tumor microenvironment. Cell Metab. 35, 961–978.e910 (2023).
Zhang, Z. et al. Malic enzyme 2 maintains metabolic state and anti-tumor immunity of CD8+ T cells. Mol. Cell. 84, 3354–3370.e3357 (2024).
Böttcher, M. et al. D-2-hydroxyglutarate interferes with HIF-1α stability skewing T-cell metabolism towards oxidative phosphorylation and impairing Th17 polarization. Oncoimmunology 7, e1445454 (2018).
Tyrakis, P. A. et al. S-2-hydroxyglutarate regulates CD8+ T-lymphocyte fate. Nature 540, 236–241 (2016).
Elia, I. et al. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8(+) T cells. Cell Metab. 34, 1137–1150.e1136 (2022).
Zhu, C. X. et al. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8(+) T cells in hepatocellular carcinoma. J. Hepatol. 81, 690–703 (2024).
Cai, Z. et al. Targeting PHGDH reverses the immunosuppressive phenotype of tumor-associated macrophages through α-ketoglutarate and mTORC1 signaling. Cell Mol. Immunol. 21, 448–465 (2024).
Raines, L. N. et al. PERK is a critical metabolic hub for immunosuppressive function in macrophages. Nat. Immunol. 23, 431–445 (2022).
Feng, S. et al. Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity. Cell Rep. 43, (2024).
Zhao, Y. et al. Neutrophils resist ferroptosis and promote breast cancer metastasis through aconitate decarboxylase 1. Cell Metab. 35, 1688–1703.e1610 (2023).
Samovski, D., Jacome-Sosa, M. & Abumrad, N. A. Fatty Acid Transport and Signaling: Mechanisms and Physiological Implications. Annu Rev. Physiol. 85, 317–337 (2023).
Ma, X. et al. CD36-mediated ferroptosis dampens intratumoral CD8+ T cell effector function and impairs their antitumor ability. Cell Metab. 33, 1001–1012.e1005 (2021).
Xu, S. et al. Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. Immunity 54, 1561–1577.e1567 (2021).
Wang, H. et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nat. Immunol. 21, 298–308 (2020).
Xu, Z. et al. Nuclear HMGB1 is critical for CD8 T cell IFN-γ production and anti-tumor immunity. Cell Rep. 43, (2024).
Zhang, H. et al. Ketogenesis-generated β-hydroxybutyrate is an epigenetic regulator of CD8+ T-cell memory development. Nat. Cell Biol. 22, 18–25 (2020).
Ping, Y. et al. PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis. Immunity 57, 2122–2139.e2129 (2024).
Li, S. et al. Metabolism drives macrophage heterogeneity in the tumor microenvironment. Cell Rep. 39, 110609 (2022).
Yang, X. et al. FABP5(+) lipid-loaded macrophages process tumor-derived unsaturated fatty acid signal to suppress T-cell antitumor immunity. J. Hepatol, (2024).
Zhang, S. et al. C1q(+) tumor-associated macrophages contribute to immunosuppression through fatty acid metabolic reprogramming in malignant pleural effusion. J. Immunother. Cancer. 11, (2023).
Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity, (2024).
Kemp, S. B. et al. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Cancer Res. 81, 4305–4318 (2021).
Mi, X. et al. The ketogenic diet modulates tumor-associated neutrophil polarization via the AMOT-YAP/TAZ axis to inhibit colorectal cancer progression. Pharm. Res. 210, 107494 (2024).
Newman, A. C. & Maddocks, O. D. K. One-carbon metabolism in cancer. Br. J. Cancer 116, 1499–1504 (2017).
Yang, M. & Vousden, K. H. Serine and one-carbon metabolism in cancer. Nat. Rev. Cancer 16, 650–662 (2016).
Sugiura, A. et al. MTHFD2 is a metabolic checkpoint controlling effector and regulatory T cell fate and function. Immunity 55, 65–81.e69 (2022).
Liu, H. et al. PRMT1-mediated PGK1 arginine methylation promotes colorectal cancer glycolysis and tumorigenesis. Cell Death Dis. 15, 170 (2024).
Rowe, J. H. et al. Formate Supplementation Enhances Antitumor CD8+ T-cell Fitness and Efficacy of PD-1 Blockade. Cancer Dis. 13, 2566–2583 (2023).
Kinoshita, M. et al. Dietary folic acid promotes survival of Foxp3+ regulatory T cells in the colon. J. Immunol. 189, 2869–2878 (2012).
Yamaguchi, T. et al. Control of Immune Responses by Antigen-Specific Regulatory T Cells Expressing the Folate Receptor. Immunity 27, 145–159 (2007).
Liang, S. C., Moskalenko, M., Van Roey, M. & Jooss, K. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clin. Immunol. 148, 287–298 (2013).
Kurniawan, H. et al. Glutathione Restricts Serine Metabolism to Preserve Regulatory T Cell Function. Cell Metab. 31, 920–936.e927 (2020).
Ma, E. H. et al. Metabolic Profiling Using Stable Isotope Tracing Reveals Distinct Patterns of Glucose Utilization by Physiologically Activated CD8(+) T Cells. Immunity 51, 856–870.e855 (2019).
Rodriguez, P. C. et al. L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J. Immunol. 171, 1232–1239 (2003).
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
Chen, S. et al. Serine Supports IL-1β Production in Macrophages Through mTOR Signaling. Front. Immunol. 11, 1866 (2020).
Fnu, G. & Weber, G. F. Alterations of Ion Homeostasis in Cancer Metastasis: Implications for Treatment. Front Oncol. 11, 765329 (2021).
Karsch-Bluman, A. et al. Tissue necrosis and its role in cancer progression. Oncogene 38, 1920–1935 (2019).
Eil, R. et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature 537, 539–543 (2016).
Vodnala, S. K. et al. T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science. 363, (2019).
Soll, D. et al. Sodium chloride in the tumor microenvironment enhances T cell metabolic fitness and cytotoxicity. Nat. Immunol. 25, 1830–1844 (2024).
Kim, K. S. et al. Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science 351, 858–863 (2016).
Campbell, C. et al. Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells. Nature 581, 475–479 (2020).
Cong, J. et al. Bile acids modified by the intestinal microbiota promote colorectal cancer growth by suppressing CD8(+) T cell effector functions. Immunity 57, 876–889.e811 (2024).
Han, S. et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci. Adv. 9, eadg2697 (2023).
Zhang, Q. et al. Lactobacillus plantarum-derived indole-3-lactic acid ameliorates colorectal tumorigenesis via epigenetic regulation of CD8(+) T cell immunity. Cell Metab. 35, 943–960.e949 (2023).
Jin, X. et al. Unveiling the methionine cycle: a key metabolic signature and NR4A2 as a methionine-responsive oncogene in esophageal squamous cell carcinoma. Cell Death Differ. (2024).
Ma, Y. et al. Intratumor microbiome-derived butyrate promotes lung cancer metastasis. Cell Rep. Med. 5, 101488 (2024).
Hezaveh, K. et al. Tryptophan-derived microbial metabolites activate the aryl hydrocarbon receptor in tumor-associated macrophages to suppress anti-tumor immunity. Immunity 55, 324–340.e328 (2022).
de Visser, K. E. & Joyce, J. A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41, 374–403 (2023).
Vitale, I. et al. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019).
Bodac, A. & Meylan, E. Neutrophil metabolism in the cancer context. Semin Immunol. 57, 101583 (2021).
Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).
Canli, Ö et al. Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell. 32, 869–883.e865 (2017).
Denk, D. & Greten, F. R. Inflammation: the incubator of the tumor microenvironment. Trends Cancer 8, 901–914 (2022).
Alonso-Curbelo, D. et al. A gene–environment-induced epigenetic program initiates tumorigenesis. Nature 590, 642–648 (2021).
Zheng, L. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 374, abe6474 (2021).
Böttcher, J. P. et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. Cell 172, 1022–1037.e1014 (2018).
Lavin, Y. et al. Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses. Cell 169, 750–765.e717 (2017).
Guimarães, G. R. et al. Single-cell resolution characterization of myeloid-derived cell states with implication in cancer outcome. Nat. Commun. 15, 5694 (2024).
Mulder, K. et al. Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease. Immunity 54, 1883–1900.e1885 (2021).
Sadik, A. et al. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression. Cell 182, 1252–1270.e1234 (2020).
Veglia, F. et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature 569, 73–78 (2019).
Srivastava, M. K. et al. Myeloid-Derived Suppressor Cells Inhibit T-Cell Activation by Depleting Cystine and Cysteine. Cancer Res. 70, 68–77 (2010).
Huang, J. et al. Extracellular matrix and its therapeutic potential for cancer treatment. Signal Transduct. Target Ther. 6, 153 (2021).
Sahai, E. et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat. Rev. Cancer 20, 174–186 (2020).
Liu, Z. et al. Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma. Int J. Oral. Sci. 16, 9 (2024).
Li, Z. et al. Tumor-produced and aging-associated oncometabolite methylmalonic acid promotes cancer-associated fibroblast activation to drive metastatic progression. Nat. Commun. 13, 6239 (2022).
Maller, O. et al. Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. Nat. Mater. 20, 548–559 (2021).
Wu, S. Z. et al. Stromal cell diversity associated with immune evasion in human triple-negative breast cancer. EMBO J. 39, e104063 (2020).
Liu, Z. L. et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct. Target Ther. 8, 198 (2023).
Folkman, J. Tumor Angiogenesis: Therapeutic Implications. N. Engl. J. Med. 285, 1182–1186 (1971).
Shaw, P. et al. VEGF signaling: Role in angiogenesis and beyond. Biochim Biophys. Acta Rev. Cancer 1879, 189079 (2024).
De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474 (2017).
Casazza, A. et al. Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity. Cancer Cell. 24, 695–709 (2013).
Biswas, S. K. Metabolic reprogramming of immune cells in cancer progression. Immunity 43, 435–449 (2015).
Wenes, M. et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 24, 701–715 (2016).
Huinen, Z. R. et al. Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes. Nat. Rev. Clin. Oncol. 18, 527–540 (2021).
Liu, Y. & Cao, X. Characteristics and Significance of the Pre-metastatic Niche. Cancer Cell. 30, 668–681 (2016).
Zhang, H. et al. Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018).
Lucotti, S., Kenific, C. M., Zhang, H. & Lyden, D. Extracellular vesicles and particles impact the systemic landscape of cancer. EMBO J. 41, e109288 (2022).
Kp, M. et al. The proteomic analysis shows enrichment of RNA surveillance pathways in adult SHH and extensive metabolic reprogramming in Group 3 medulloblastomas. Brain Tumor Pathol. 38, 96–108 (2021).
Freag, M. S. et al. Modulating tumoral exosomes and fibroblast phenotype using nanoliposomes augments cancer immunotherapy. Sci. Adv. 11, e3074 (2024).
Fong, M. Y. et al. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015).
Tian, X. et al. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J. Hematol. Oncol. 12, 84 (2019).
Wang, G. et al. Tumour extracellular vesicles and particles induce liver metabolic dysfunction. Nature 618, 374–382 (2023).
Morrissey, S. M. et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 33, 2040–2058.e2010 (2021).
Zhang, C. et al. Cancer-derived exosomal HSPC111 promotes colorectal cancer liver metastasis by reprogramming lipid metabolism in cancer-associated fibroblasts. Cell Death Dis. 13, 57 (2022).
Dai, J. et al. Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis. J. Exp. Med. 216, 2883–2899 (2019).
Mercier, F. E., Ragu, C. & Scadden, D. T. The bone marrow at the crossroads of blood and immunity. Nat. Rev. Immunol. 12, 49–60 (2012).
Brodt, P. Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. Clin. Cancer Res. 22, 5971–5982 (2016).
Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 9, 285–293 (2009).
Ma, C. et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 360, (2018).
Ishibashi, K. et al. Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Dev. Cell. 59, 579–594.e576 (2024).
Venkataramani, V. et al. Glutamatergic synaptic input to glioma cells drives brain tumour progression. Nature 573, 532–538 (2019).
Zeng, Q. et al. Synaptic proximity enables NMDAR signalling to promote brain metastasis. Nature 573, 526–531 (2019).
Cords, L. et al. Cancer-associated fibroblast classification in single-cell and spatial proteomics data. Nat. Commun. 14, 4294 (2023).
Xu, X. et al. Integrating single-cell RNA sequencing data to decipher heterogeneity and function of macrophages in various organs and diseases. Clin. Trans. Discov. 4, e70005 (2024).
Jenkins, L. et al. Cancer-Associated Fibroblasts Suppress CD8+ T-cell Infiltration and Confer Resistance to Immune-Checkpoint Blockade. Cancer Res. 82, 2904–2917 (2022).
Elyada, E. et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 9, 1102–1123 (2019).
Zhang, K. et al. Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer. Nat. Commun. 15, 9050 (2024).
Chung, B. et al. Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12. NPJ Breast Cancer 3, 6 (2017).
Wang, H. et al. Binding mode of the side-by-side two-IgV molecule CD226/DNAM-1 to its ligand CD155/Necl-5. Proc. Natl Acad. Sci. USA. 116, 988–996 (2019).
Raymant, M. et al. Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Nat. Commun. 15, 3593 (2024).
Xu, Y. et al. Osteosarcoma Cells Secrete CXCL14 That Activates Integrin α11β1 on Fibroblasts to Form a Lung Metastatic Niche. Cancer Res. 84, 994–1012 (2024).
Wang, Y. et al. Targeting Src SH3 domain-mediated glycolysis of HSC suppresses transcriptome, myofibroblastic activation, and colorectal liver metastasis. Hepatology 80, 578–594 (2024).
Yu, Y. et al. Hepatic stellate cells promote hepatocellular carcinoma development by regulating histone lactylation: Novel insights from single-cell RNA sequencing and spatial transcriptomics analyses. Cancer Lett. 604, 217243 (2024).
Chen, Q. T. et al. HK1 from hepatic stellate cell-derived extracellular vesicles promotes progression of hepatocellular carcinoma. Nat. Metab. 4, 1306–1321 (2022).
Sousa, C. M. et al. Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016).
Anderson, K. G., Stromnes, I. M. & Greenberg, P. D. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies. Cancer Cell. 31, 311–325 (2017).
Puré, E. & Lo, A. Can targeting stroma pave the way to enhanced antitumor immunity and immunotherapy of solid tumors?. Cancer Immunol. Res. 4, 269–278 (2016).
Kloosterman, D. J. et al. Macrophage-mediated myelin recycling fuels brain cancer malignancy. Cell 187, 5336–5356.e5330 (2024).
Wang, T. et al. Influenza-trained mucosal-resident alveolar macrophages confer long-term antitumor immunity in the lungs. Nat. Immunol. 24, 423–438 (2023).
Chang, C.-Y. et al. Chronic exposure to carbon black ultrafine particles reprograms macrophage metabolism and accelerates lung cancer. Sci. Adv. 8, eabq0615 (2022).
Thomas, S. K. et al. Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nat. Commun. 14, 6330 (2023).
Jackson, C. M., Choi, J. & Lim, M. Mechanisms of immunotherapy resistance: lessons from glioblastoma. Nat. Immunol. 20, 1100–1109 (2019).
Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39 (2020).
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell 168, 707–723 (2017).
O’Sullivan, D., Sanin, D. E., Pearce, E. J. & Pearce, E. L. Metabolic interventions in the immune response to cancer. Nat. Rev. Immunol. 19, 324–335 (2019).
Li, H. et al. Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nat. Commun. 10, 4346 (2019).
Min, L. et al. Cellular cytotoxicity is a form of immunogenic cell death. J. ImmunoTher. Cancer 8, e000325 (2020).
Zhou, Z. et al. Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 368, (2020).
Byun, J.-K. et al. Inhibition of Glutamine Utilization Synergizes with Immune Checkpoint Inhibitor to Promote Antitumor Immunity. Mol. Cell. 80, 592–606.e598 (2020).
Wang, W. et al. CD8(+) T cells regulate tumour ferroptosis during cancer immunotherapy. Nature 569, 270–274 (2019).
Chen, X., Yu, C., Kang, R. & Tang, D. Iron Metabolism in Ferroptosis. Front Cell Dev. Biol. 8, 590226 (2020).
Liao, P. et al. CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4. Cancer Cell. 40, 365–378.e366 (2022).
Lin, H. et al. Itaconate transporter SLC13A3 impairs tumor immunity via endowing ferroptosis resistance. Cancer Cell. 42, 2032–2044.e2036 (2024).
Zhao, L. et al. Lactate dehydrogenase B noncanonically promotes ferroptosis defense in KRAS-driven lung cancer. Cell Death Differ. (2024).
Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 12, 599–620 (2021).
Shen, X. et al. Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosis. Cell Rep. Med. 101928, (2025).
Han, Y. et al. IL-1β-associated NNT acetylation orchestrates iron-sulfur cluster maintenance and cancer immunotherapy resistance. Mol. Cell. 83, 1887–1902.e1888 (2023).
Gui, X. et al. Autophagy induction via STING trafficking is a primordial function of the cGAS pathway. Nature 567, 262–266 (2019).
Dikic, I. & Elazar, Z. Mechanism and medical implications of mammalian autophagy. Nat. Rev. Mol. Cell Biol. 19, 349–364 (2018).
Lawson, K. A. et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature 586, 120–126 (2020).
Liu, D. et al. STING directly activates autophagy to tune the innate immune response. Cell Death Differ. 26, 1735–1749 (2019).
Yamamoto, K. et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature 581, 100–105 (2020).
Liu, D. et al. Targeting the TRIM14/USP14 Axis Enhances Immunotherapy Efficacy by Inducing Autophagic Degradation of PD-L1. Cancer Res. 84, 2806–2819 (2024).
Liang, X. H. et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature 402, 672–676 (1999).
Ladoire, S. et al. The presence of LC3B puncta and HMGB1 expression in malignant cells correlate with the immune infiltrate in breast cancer. Autophagy 12, 864–875 (2016).
Li, Z. L. et al. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat. Commun. 11, 3806 (2020).
Kimmelman, A. C. & White, E. Autophagy and Tumor Metabolism. Cell Metab. 25, 1037–1043 (2017).
White, E. Deconvoluting the context-dependent role for autophagy in cancer. Nat. Rev. Cancer 12, 401–410 (2012).
Wang, L. et al. ADSL promotes autophagy and tumor growth through fumarate-mediated Beclin1 dimethylation. Nat Chem Biol, (2025).
Li, X. et al. The TORC1 activates Rpd3L complex to deacetylate Ino80 and H2A.Z and repress autophagy. Sci. Adv. 9, eade8312 (2023).
Champiat, S. et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin. Cancer Res. 23, 1920–1928 (2017).
Kato, S. et al. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin. Cancer Res. 23, 4242–4250 (2017).
Wang, Q., Gao, J. & Wu, X. Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol. 58, 125–135 (2018).
Li, G. et al. Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy. Cancer Cell. 41, 304–322.e307 (2023).
Zhou, J. X. et al. IFN regulatory factor 8 regulates MDM2 in germinal center B cells. J. Immunol. 183, 3188–3194 (2009).
Zhao, Y., Yu, H. & Hu, W. The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys. Sin. 46, 180–189 (2014).
Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495–499 (2017).
Lamichhane, P. et al. IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Res. 77, 6667–6678 (2017).
Solaymani-Mohammadi, S. et al. Lack of the programmed death-1 receptor renders host susceptible to enteric microbial infection through impairing the production of the mucosal natural killer cell effector molecules. J. Leukoc. Biol. 99, 475–482 (2016).
Dahan, R. et al. FcγRs Modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 Axis. Cancer Cell. 28, 543 (2015).
Lo Russo, G. et al. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin. Cancer Res. 25, 989–999 (2019).
Zhang, T. et al. The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunol. Immunother. 67, 1079–1090 (2018).
Zhang, J. et al. IL-4/IL-4R axis signaling drives resistance to immunotherapy by inducing the upregulation of Fcγ receptor IIB in M2 macrophages. Cell Death Dis. 15, 500 (2024).
Reticker-Flynn, N. E. et al. Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell 185, 1924–1942.e1923 (2022).
Huang, Q. et al. The primordial differentiation of tumor-specific memory CD8(+) T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodes. Cell 185, 4049–4066.e4025 (2022).
Fransen, M. F. et al. Tumor-draining lymph nodes are pivotal in PD-1/PD-L1 checkpoint therapy. JCI Insight. 3, (2018).
Li, G. et al. TGF-β-dependent lymphoid tissue residency of stem-like T cells limits response to tumor vaccine. Nat. Commun. 13, 6043 (2022).
Peng, J.-M. & Su, Y.-L. Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis. Biochem Pharmacol. 215, 115731 (2023).
Núñez, N. G. et al. Tumor invasion in draining lymph nodes is associated with Treg accumulation in breast cancer patients. Nat. Commun. 11, 3272 (2020).
Wu, H. et al. T-cells produce acidic niches in lymph nodes to suppress their own effector functions. Nat. Commun. 11, 4113 (2020).
Koukourakis, M. I. et al. Oxygen and glucose consumption in gastrointestinal adenocarcinomas: correlation with markers of hypoxia, acidity and anaerobic glycolysis. Cancer Sci. 97, 1056–1060 (2006).
Clambey, E. T. et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl Acad. Sci. USA. 109, E2784–E2793 (2012).
Koukourakis, M. I. & Giatromanolaki, A. Warburg effect, lactate dehydrogenase, and radio/chemo-therapy efficacy. Int J. Radiat. Biol. 95, 408–426 (2019).
Lee, C. K. et al. Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science 363, 644–649 (2019).
Miao, Y. et al. The role of GLS1-mediated glutaminolysis/2-HG/H3K4me3 and GSH/ROS signals in Th17 responses counteracted by PPARγ agonists. Theranostics 11, 4531–4548 (2021).
Ubellacker, J. M. et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature 585, 113–118 (2020).
de Boer, J. F. et al. New insights in the multiple roles of bile acids and their signaling pathways in metabolic control. Curr. Opin. Lipidol. 29, 194–202 (2018).
Yuan, L. et al. Fatty Acid Oxidation Supports Lymph Node Metastasis of Cervical Cancer via Acetyl-CoA-Mediated Stemness. Adv. Sci. e2308422, (2024).
Zhou, C. et al. Meningeal lymphatics regulate radiotherapy efficacy through modulating anti-tumor immunity. Cell Res. 32, 543–554 (2022).
Cousin, N. et al. Lymphatic PD-L1 Expression Restricts Tumor-Specific CD8(+) T-cell Responses. Cancer Res. 81, 4133–4144 (2021).
Simonds, E. F. et al. Deep immune profiling reveals targetable mechanisms of immune evasion in immune checkpoint inhibitor-refractory glioblastoma. J. ImmunoTher. Cancer 9, e002181 (2021).
Lee, J. C. et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci. Immunol. 5, (2020).
Yu, J. et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat. Med. 27, 152–164 (2021).
Reck, M. et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir. Med. 7, 387–401 (2019).
Daud, A. I. et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. J. Clin. Invest. 126, 3447–3452 (2016).
Li, H. et al. Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology 56, 1342–1351 (2012).
Limmer, A. et al. Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance. Nat. Med. 6, 1348–1354 (2000).
Warren, A. et al. T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44, 1182–1190 (2006).
Goubier, A. et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 29, 464–475 (2008).
Horst, A. K., Neumann, K., Diehl, L. & Tiegs, G. Modulation of liver tolerance by conventional and nonconventional antigen-presenting cells and regulatory immune cells. Cell Mol. Immunol. 13, 277–292 (2016).
du Bois, H., Heim, T. A. & Lund, A. W. Tumor-draining lymph nodes: At the crossroads of metastasis and immunity. Sci. Immunol. 6, eabg3551 (2021).
Xiao, J. et al. 25-Hydroxycholesterol regulates lysosome AMP kinase activation and metabolic reprogramming to educate immunosuppressive macrophages. Immunity 57, 1087–1104.e1087 (2024).
Pérez-González, A., Bévant, K. & Blanpain, C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat. Cancer 4, 1063–1082 (2023).
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
Feng, J. et al. Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells. Oncogene 36, 5829–5839 (2017).
Hirschhaeuser, F., Sattler, U. G. & Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res. 71, 6921–6925 (2011).
Daneshmandi, S., Wegiel, B. & Seth, P. Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma. Cancers. 11, (2019).
Scharping, N. E. et al. Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol. Res. 5, 9–16 (2017).
Sukumar, M. et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J. Clin. Invest. 123, 4479–4488 (2013).
Guo, Y. et al. Metabolic reprogramming of terminally exhausted CD8(+) T cells by IL-10 enhances anti-tumor immunity. Nat. Immunol. 22, 746–756 (2021).
Taylor, A. et al. Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses. Immunity 44, 274–286 (2016).
Leone, R. D. et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science 366, 1013–1021 (2019).
Geiger, R. et al. L-Arginine Modulates T CELL METABOLISM AND ENHANCES SURVIVAL AND ANTI-TUMOR Activity. Cell 167, 829–842.e813 (2016).
Kim, H. & Ronai, Z. A. PRMT5 function and targeting in cancer. Cell Stress. 4, 199–215 (2020).
Hu, R. et al. PRMT5 Inhibition Promotes PD-L1 Expression and Immuno-Resistance in Lung Cancer. Front Immunol. 12, 722188 (2021).
Zhai, L. et al. Immunosuppressive IDO in Cancer: Mechanisms OF ACTION, ANIMAL MODELS, AND TARGETING STRATEgies. Front Immunol. 11, 1185 (2020).
Ladomersky, E. et al. IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma. Clin. Cancer Res. 24, 2559–2573 (2018).
Gomes, B. et al. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy. Mol. Cancer Ther. 17, 2530–2542 (2018).
Zhang, Y. et al. Enhancing CD8(+) T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. Cancer Cell. 32, 377–391.e379 (2017).
Yang, W. et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism. Nature 531, 651–655 (2016).
Zhu, Y. et al. Ceramide-mediated gut dysbiosis enhances cholesterol esterification and promotes colorectal tumorigenesis in mice. JCI Insight. 7, (2022).
Fong, L. et al. Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer Discov. 10, 40–53 (2020).
Roulois, D. et al. DNA-Demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015).
Fratta, E. et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential. Mol. Oncol. 5, 164–182 (2011).
Guo, R. et al. Combination of epidrugs with immune checkpoint inhibitors in cancer immunotherapy: From theory to therapy. Int Immunopharmacol. 120, 110417 (2023).
Ramsuran, V. et al. Epigenetic regulation of differential HLA-A allelic expression levels. Hum. Mol. Genet. 24, 4268–4275 (2015).
Jones, P. A., Ohtani, H., Chakravarthy, A. & De Carvalho, D. D. Epigenetic therapy in immune-oncology. Nat. Rev. Cancer 19, 151–161 (2019).
Luo, N. et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat. Commun. 9, 248 (2018).
Yu, G. et al. Low-dose decitabine enhances the effect of PD-1 blockade in colorectal cancer with microsatellite stability by re-modulating the tumor microenvironment. Cell Mol. Immunol. 16, 401–409 (2019).
Ghoneim, H. E. et al. De Novo Epigenetic Programs Inhibit PD-1 Blockade-Mediated T Cell Rejuvenation. Cell 170, 142–157.e119 (2017).
Orillion, A. et al. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin. Cancer Res. 23, 5187–5201 (2017).
Woods, D. M. et al. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol. Res. 3, 1375–1385 (2015).
Zheng, H. et al. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin. Cancer Res. 22, 4119–4132 (2016).
Llopiz, D. et al. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. Cancer Immunol. Immunother. 68, 379–393 (2019).
Zingg, D. et al. The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy. Cell Rep. 20, 854–867 (2017).
Qin, Y. et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade. Oncogene 38, 390–405 (2019).
Adeegbe, D. O. et al. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol. Res. 6, 1234–1245 (2018).
Mardiana, S., Solomon, B. J., Darcy, P. K. & Beavis, P. A. Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression. Sci. Trans. Med. 11, eaaw2293 (2019).
Vo, D. D. et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 69, 8693–8699 (2009).
Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307–312 (2018).
Powell, D. J. Jr., Dudley, M. E., Robbins, P. F. & Rosenberg, S. A. Transition of late-stage effector T cells to CD27+ CD28+ tumor-reactive effector memory T cells in humans after adoptive cell transfer therapy. Blood 105, 241–250 (2005).
Qiu, F. et al. Priming with LSD1 inhibitors promotes the persistence and antitumor effect of adoptively transferred T cells. Nat. Commun. 15, 4327 (2024).
Pace, L. et al. The epigenetic control of stemness in CD8(+) T cell fate commitment. Science 359, 177–186 (2018).
Kagoya, Y. et al. BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. J. Clin. Invest. 126, 3479–3494 (2016).
Quandt, D. et al. Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J. Transl. Med. 12, 151 (2014).
Quan, Z. et al. Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. J. Cancer 13, 3434–3443 (2022).
Zhang, N. et al. The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. Int J. Oncol. 49, 1360–1368 (2016).
Stutvoet, T. S. et al. MAPK pathway activity plays a key role in PD-L1 expression of lung adenocarcinoma cells. J. Pathol. 249, 52–64 (2019).
Gao, Y. et al. IFN-γ-mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. Int J. Cancer 143, 931–943 (2018).
Ren, B. et al. High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. J. Hematol. Oncol. 14, 120 (2021).
Lee, Y. H. et al. Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2. Cancer Res. 74, 4752–4761 (2014).
Wan, W. et al. Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1α. Oncogene 36, 3868–3877 (2017).
Chen, E. et al. FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity. Nat. Commun. 15, 4590 (2024).
Pedersen, P. L. et al. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim Biophys. Acta 1555, 14–20 (2002).
Nimmakayala, R. K. et al. Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma. Oncogene 40, 215–231 (2021).
Sluiter, N. et al. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin. Exp. Metastasis. 33, 401–416 (2016).
Di Biase, S. et al. Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell. 30, 136–146 (2016).
De Rosa, V. et al. Glycolysis controls the induction of human regulatory T cells by modulating the expression of FOXP3 exon 2 splicing variants. Nat. Immunol. 16, 1174–1184 (2015).
Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436–443 (2015).
Di Biase, S. et al. Creatine uptake regulates CD8 T cell antitumor immunity. J. Exp. Med. 216, 2869–2882 (2019).
Wyss, M. & Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev. 80, 1107–1213 (2000).
Kava, M. P. et al. Beneficial outcome of early dietary lysine restriction as an adjunct to pyridoxine therapy in a child with pyridoxine dependant epilepsy due to Antiquitin deficiency. JIMD Rep. 54, 9–15 (2020).
Michelet, X. et al. Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat. Immunol. 19, 1330–1340 (2018).
Font-Burgada, J., Sun, B. & Karin, M. Obesity and Cancer: The Oil that Feeds the Flame. Cell Metab. 23, 48–62 (2016).
Zhang, C. et al. STAT3 Activation-Induced Fatty Acid Oxidation in CD8(+) T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Cell Metab. 31, 148–161.e145 (2020).
Wang, Y. Y. et al. Adipose tissue and breast epithelial cells: a dangerous dynamic duo in breast cancer. Cancer Lett. 324, 142–151 (2012).
Zhu, X. et al. Interplay between gut microbial communities and metabolites modulates pan-cancer immunotherapy responses. Cell Metab. (2025).
Jia, D. et al. Microbial metabolite enhances immunotherapy efficacy by modulating T cell stemness in pan-cancer. Cell 187, 1651–1665.e1621 (2024).
Ren, B. et al. Microbiota-metabolism-epigenetics-immunity axis in cancer. Front Immunol. 15, 1449912 (2024).
He, Y. et al. Gut microbial metabolites facilitate anticancer therapy efficacy by modulating cytotoxic CD8(+) T cell immunity. Cell Metab. 33, 988–1000.e1007 (2021).
Fernandes, M. R. et al. Targeting the gut microbiota for cancer therapy. Nat. Rev. Cancer 22, 703–722 (2022).
Zhang, S. et al. Hurdle or thruster: Glucose metabolism of T cells in anti-tumour immunity. Biochim Biophys. Acta Rev. Cancer 1879, 189022 (2024).
Zhao, E. et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat. Immunol. 17, 95–103 (2016).
Sade-Feldman, M. et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 175, 998–1013.e1020 (2018).
Tay, R. E. et al. Correction: Hdac3 is an epigenetic inhibitor of the cytotoxicity program in CD8 T cells. J. Exp. Med. 217, (2020).
Olson, B. et al. Mouse Models for Cancer Immunotherapy Research. Cancer Discov. 8, 1358–1365 (2018).
Soudah, T., Zoabi, A. & Margulis, K. Desorption electrospray ionization mass spectrometry imaging in discovery and development of novel therapies. Mass Spectrom. Rev. 42, 751–778 (2023).
Li, W. et al. scNanoHi-C: a single-cell long-read concatemer sequencing method to reveal high-order chromatin structures within individual cells. Nat. Methods 20, 1493–1505 (2023).
Zou, C., Wang, Y. & Shen, Z. 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J. Biochem Biophys. Methods 64, 207–215 (2005).
Li, X. et al. Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease. Cell Metab. 35, 200–211.e209 (2023).
Chen, X. et al. ATAC-see reveals the accessible genome by transposase-mediated imaging and sequencing. Nat. Methods 13, 1013–1020 (2016).
Baysoy, A., Bai, Z., Satija, R. & Fan, R. The technological landscape and applications of single-cell multi-omics. Nat. Rev. Mol. Cell Biol. 24, 695–713 (2023).
Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81–94 (2018).
Wang, X. et al. Comprehensive multi-omics profiling identifies novel molecular subtypes of pancreatic ductal adenocarcinoma. Genes Dis. 11, 101143 (2024).
Jiang, Z. et al. A Potential “Anti-Warburg Effect” in Circulating Tumor Cell-mediated Metastatic Progression?. Aging Dis. 16, 269–282 (2024).
Xu, K. et al. Integrative analyses of scRNA-seq and scATAC-seq reveal CXCL14 as a key regulator of lymph node metastasis in breast cancer. Hum. Mol. Genet. 30, 370–380 (2021).
Chung, C. et al. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell. 38, 334–349.e339 (2020).
Liang, L. et al. Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. Nat. Genet. 57, 680–693 (2025).
Elia, I. et al. Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature 568, 117–121 (2019).
Wang, Z. J. et al. Hyperpolarized 13C MRI: State of the art and future directions. Radiology 291, 273–284 (2019).
Oliver, J. et al. Emerging noninvasive methylation biomarkers of cancer prognosis and drug response prediction. Semin Cancer Biol. 83, 584–595 (2022).
Zhang, Z. et al. Increased hyaluronan by naked mole-rat Has2 improves healthspan in mice. Nature 621, 196–205 (2023).
Vollrath, F. Uncoupling elephant TP53 and cancer. Trends Ecol. Evol. 38, 705–707 (2023).
Clem, B. F. et al. Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer. Mol. Cancer Ther. 12, 1461–1470 (2013).
Gao, W. et al. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells. J. Immunother. Cancer 7, 231 (2019).
Chang, K. Y. et al. Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology 10, 1943253 (2021).
Naing, A. et al. 440O – Phase I study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (adv/met) solid tumours. Ann. Oncol. 30, v160 (2019).
Silk, A. W. et al. A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. Eur. J. Med. Res. 27, 107 (2022).
Borodovsky, A. et al. Small molecule AZD4635 inhibitor of A(2A)R signaling rescues immune cell function including CD103(+) dendritic cells enhancing anti-tumor immunity. J. Immunother. Cancer. 8, (2020).
Bendell, J. et al. Abstract CT026: Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Cancer Res. 79, CT026–CT026 (2019).
Wang, L. et al. Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model. Cancer Immunol. Res. 3, 1030–1041 (2015).
Chiappinelli, K. B. et al. Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 162, 974–986 (2015).
Bouligny, I. M. et al. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39, 524–528 (2025).
Abbas, H. A. et al. Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. Nat. Commun. 12, 6071 (2021).
Verma, A. et al. Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. Cancers. 16, (2024).
Licht, J. D. DNA Methylation Inhibitors in Cancer Therapy: The Immunity Dimension. Cell 162, 938–939 (2015).
Wen, Y. et al. Immune checkpoints in osteosarcoma: Recent advances and therapeutic potential. Cancer Lett. 547, 215887 (2022).
da Costa, A. A. B. A. & Baiocchi, G. Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets. Semin Cancer Biol. 77, 29–41 (2021).
Liu, Y. et al. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma. J. Immunother. Cancer. 9, (2021).
Kang, K. et al. Tetrahydrouridine/decitabine/5-azacytidine for non-cytotoxic epigenetic-immunotherapy of NSCLC in vivo. J. Clin. Oncol. 36, e24134-e24134.
Zheng, H. et al. A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. Am. J. Hematol. 96, (2020).
Stein, A. et al. Immuno-oncology in GI tumours: Clinical evidence and emerging trials of PD-1/PD-L1 antagonists. Crit. Rev. Oncol. Hematol. 130, 13–26 (2018).
Borcoman, E. et al. HDAC Inhibition to Prime Immune Checkpoint Inhibitors. Cancers. 14, (2021).
Fang, C., Wang, Y. & Li, Y. Research Progress of Histone Deacetylase Inhibitor Combined with Immune Checkpoint Inhibitor in the Treatment of Tumor]. Chin. J. Lung Cancer 24, 204–211 (2021).
Awad, M. M. et al. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Front Oncol. 11, 696512 (2021).
Cadoo, K. A. et al. A phase II randomized study of avelumab plus entinostat versus avelumab plus placebo in patients (pts) with advanced epithelial ovarian cancer (EOC). J. Clin. Oncol. 37, 5511-5511.
O’Shaughnessy, J. et al. Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). J. Clin. Oncol. 38, 1014-1014.
Johnson, M. L. et al. Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study. Clin. Lung Cancer 24, 218–227 (2023).
Shin, D. S., Park, K., Garon, E. & Dubinett, S. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Semin Oncol. 49, 306–318 (2022).